Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Walker, 1980, Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery, N Engl J Med, 303, 1323, 10.1056/NEJM198012043032303

Laperriere, 2002, Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review, Radiother Oncol, 64, 259, 10.1016/S0167-8140(02)00078-6

Stewart, 2002, Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials, Lancet, 359, 1011, 10.1016/S0140-6736(02)08091-1

Stupp, 2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 352, 987, 10.1056/NEJMoa043330

Hegi, 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma, N Engl J Med, 352, 997, 10.1056/NEJMoa043331

Pocock, 1975, Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial, Biometrics, 31, 103, 10.2307/2529712

Freedman, 1976, On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial, Biometrics, 32, 691, 10.2307/2529759

Ataman, 2004, Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review, Eur J Cancer, 40, 1724, 10.1016/j.ejca.2004.03.026

Taphoorn, 2005, Health-related quality of life in patients with glioblastoma: a randomised controlled trial, Lancet Oncol, 6, 937, 10.1016/S1470-2045(05)70432-0

Mirimanoff, 2006, Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial, J Clin Oncol, 24, 2563, 10.1200/JCO.2005.04.5963

Lamers, 2008, Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study, Cancer, 112, 1337, 10.1002/cncr.23297

Gonzalez, 1994, Accelerated radiotherapy in glioblastoma multiforme: a dose searching prospective study, Radiother Oncol, 32, 98, 10.1016/0167-8140(94)90095-7

Miralbell, 1999, Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933, J Clin Oncol, 17, 3143, 10.1200/JCO.1999.17.10.3143

Newlands, 1997, Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials, Cancer Treat Rev, 23, 35, 10.1016/S0305-7372(97)90019-0

Brock, 1998, Phase I trial of temozolomide using an extended continuous oral schedule, Cancer Res, 58, 4363

Yung, 2000, A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse, Br J Cancer, 83, 588, 10.1054/bjoc.2000.1316

Brada, 2001, Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse, Ann Oncol, 12, 259, 10.1023/A:1008382516636

Stupp, 2002, Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide, J Clin Oncol, 20, 1375, 10.1200/JCO.20.5.1375

Wick, 2008, A novel tool to analyse MRI recurrence patterns in glioblastoma, Neuro Oncol, 10, 1019, 10.1215/15228517-2008-058

Brandes, 2008, MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients, J Clin Oncol, 26, 2192, 10.1200/JCO.2007.14.8163

2001, Randomized trial of procarbazine, lomustine and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial, J Clin Oncol, 19, 509, 10.1200/JCO.2001.19.2.509

Wedge, 1997, In vitro evaluation of temozolomide combined with X-irradiation, Anticancer Drugs, 8, 92, 10.1097/00001813-199701000-00013

Hirose, 2001, p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells, Cancer Res, 61, 1957

van Rijn, 2000, Survival of human glioma cells treated with various combination of temozolomide and X-rays, Int J Radiat Oncol Biol Phys, 47, 779, 10.1016/S0360-3016(99)00539-8

Wick, 2002, Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase, Cancer Res, 62, 1915

Chakravarti, 2006, Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms, Clin Cancer Res, 12, 4738, 10.1158/1078-0432.CCR-06-0596

Curran, 1993, Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials, J Natl Cancer Inst, 85, 704, 10.1093/jnci/85.9.704

Behin, 2003, Primary brain tumours in adults, Lancet, 361, 323, 10.1016/S0140-6736(03)12328-8

Gorlia, 2008, Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3, Lancet Oncol, 9, 29, 10.1016/S1470-2045(07)70384-4

Stummer, 2006, Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial, Lancet Oncol, 7, 392, 10.1016/S1470-2045(06)70665-9

Schilsky, 2008, How not to treat cancer, Lancet Oncol, 9, 504, 10.1016/S1470-2045(08)70134-7

Gerson, 2002, Clinical relevance of MGMT in the treatment of cancer, J Clin Oncol, 20, 2388, 10.1200/JCO.2002.06.110

Gerson, 2004, MGMT: its role in cancer aetiology and cancer therapeutics, Nat Rev Cancer, 4, 296, 10.1038/nrc1319

Ochs, 2000, Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent, Cancer Res, 60, 5815

Esteller, 2000, Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents, N Engl J Med, 343, 1350, 10.1056/NEJM200011093431901

Hegi, 2004, Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide, Clin Cancer Res, 10, 1871, 10.1158/1078-0432.CCR-03-0384

Jaeckle, 1998, Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study, J Clin Oncol, 16, 3310, 10.1200/JCO.1998.16.10.3310

Criniere, 2007, MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities, J Neurooncol, 83, 173, 10.1007/s11060-006-9320-0

Hegi, 2008, Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity, J Clin Oncol, 26, 4189, 10.1200/JCO.2007.11.5964

Murat, 2008, Stem cell-related «self-renewal» signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma, J Clin Oncol, 26, 3015, 10.1200/JCO.2007.15.7164

Vredenburgh, 2007, Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma, Clin Cancer Res, 13, 1253, 10.1158/1078-0432.CCR-06-2309

Batchelor, 2007, AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients, Cancer Cell, 11, 83, 10.1016/j.ccr.2006.11.021

Kreisl, 2008, Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma, J Clin Oncol, 27, 740, 10.1200/JCO.2008.16.3055

Stupp, 2007, Chemoradiotherapy in malignant glioma: standard of care and future directions, J Clin Oncol, 25, 4127, 10.1200/JCO.2007.11.8554

Reardon, 2008, Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme, J Clin Oncol, 26, 5610, 10.1200/JCO.2008.16.7510

Reardon, 2008, Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme, Expert Opin Investig Drugs, 17, 1225, 10.1517/13543784.17.8.1225

Omuro, 2007, Lessons learned in the development of targeted therapy for malignant gliomas, Mol Cancer Ther, 6, 1909, 10.1158/1535-7163.MCT-07-0047

Stupp, 2007, Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients with newly diagnosed glioblastoma, J Clin Oncol, 25, 75s

Wen, 2008, Malignant gliomas in adults, N Engl J Med, 359, 492, 10.1056/NEJMra0708126

van den Bent, 2009, Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma, J Clin Oncol, 10.1200/JCO.2008.17.5984